Celyad Oncology Company Description

Celyad Oncology SA, a biotechnology company, focuses on research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.

The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells.

It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells.

The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Celyad Oncology SA

Country	Belgium
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	19
CEO	Matthew Kane

Contact Details

Address: Rue André Dumont 9 Mont-Saint-Guibert, 1435 Belgium
Phone	32 1 039 41 00
Website	celyad.com

Stock Details

Ticker Symbol	CYAD
Exchange	Euronext Brussels
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	BE0974260896
SIC Code	2836

Key Executives

Name	Position
Matthew R. Kane	Chief Executive Officer and Executive Director
Michel E. J. Lussier BME, M.B.A., M.S., MS BME	Co-Founder and Non-Executive Director
David Georges	Vice President of Finance and Administration
Sara Zelkovic	Communications and Investor Relations Director
An Phan	Head of Legal
Hannes Iserentant	Head of Intellectual Property
Eytan Breman	Head of Research & Development
Philippe Dechamps	Corporate Secretary